Related Experiment Video

Updated: Mar 14, 2026

Guidelines for Elective Pediatric Fiberoptic Intubation
11:19

Guidelines for Elective Pediatric Fiberoptic Intubation

Published on: January 17, 2011

18.8K

Notice of Changes to Compleat Pediatric 1.0

    Nutrition in Clinical Practice : Official Publication of the American Society for Parenteral and Enteral Nutrition
    |October 1, 2016
    PubMed

    Insights

    This study evaluated a real-food-ingredient tube feeding formula for pediatric intestinal failure. Results from the original formula may not apply to the updated version with new ingredients.

    Area of Science:

    • Pediatric Gastroenterology
    • Clinical Nutrition
    • Intestinal Rehabilitation

    Background:

    • Intestinal failure (IF) in children necessitates specialized nutrition support.
    • Tube feeding formulas aim to mimic oral diets but often lack real food components.
    • Transitioning to whole-food-based formulas may improve outcomes in pediatric IF.

    Purpose of the Study:

    • To assess the efficacy and tolerability of a real-food-ingredient enteral formula in pediatric patients with IF.
    • To evaluate clinical outcomes, growth, and gastrointestinal tolerance in this population.

    Main Methods:

    • A cohort of pediatric patients with IF transitioned to a specific real-food-ingredient formula.
    • Clinical data including growth parameters, stool output, and tolerance were collected.
    • Nutritional adequacy and patient outcomes were monitored post-transition.

    Main Results:

    • The study authors noted that the product formulation changed post-publication.
    • The original formula's results may not be reproducible with the new formulation (including FOS, pea protein, and inulin).
    • Authors stand by their results with the original formula.

    Conclusions:

    • The original formula showed promise for managing pediatric intestinal failure.
    • A product formulation change necessitates caution regarding the reproducibility of the study's findings.
    • Further research is needed to evaluate the updated formula's efficacy.

    More Related Videos

    A Modified Sonographic Algorithm for Image Acquisition in Life-Threatening Emergencies in the Critically Ill Newborn11:27

    A Modified Sonographic Algorithm for Image Acquisition in Life-Threatening Emergencies in the Critically Ill Newborn

    Published on: April 7, 2023

    7.7K
    Whole-body PET/MRI of Pediatric Patients: The Details That Matter10:02

    Whole-body PET/MRI of Pediatric Patients: The Details That Matter

    Published on: December 19, 2017

    15.5K

    Related Concept Videos

    Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

    Pharmacokinetics in Pediatric Patients: Drug Excretion

    In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
    349
    Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

    Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

    Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
    631
    Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

    Pharmacokinetics in Pediatric Patients: Drug Distribution

    Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
    419
    Drug Dosing: Infants and Children01:29

    Drug Dosing: Infants and Children

    Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
    677
    Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

    Pharmacokinetics in Pediatric Patients: Drug Metabolism

    In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
    312
    FDA Approved Drugs: Changes to Approved Drugs01:26

    FDA Approved Drugs: Changes to Approved Drugs

    Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
    313